Eton Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryDrug Manufacturers - Specialty & Generic Beta (adjusted)0.92 Intrinsic Value $21.69median of 3 methodsbased on filings through 30 Jun 2026 Market Price $51.98Price as of 1 Oct 2026 Significantly overvaluedIntrinsic value is 58% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-58%) Data confidence Sign in to view data confidence Market Cap $1.5B Enterprise Value $1.5B Shares Outstanding 27.5M diluted Moat Rating Wide Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Eton Pharmaceuticals is executing a highly efficient, low-risk acquisition-and-commercialization model focused on orphan and ultra-rare disease therapies. By targeting small patient populations that are structurally insulated from price wars and big pharma competition, Eton secures high-margin, long-duration revenue streams. The company's recent financial performance demonstrates rapid operational scaling, highlighted by a 73% year-over-year increase in Q1 2026 product sales to $24.3 million and an upward revision of full-year 2026 revenue guidance to over $120 million. With a clear path to achieving a $200 million run rate exiting 2027 and a long-term target of $500 million by 2030, Eton represents a compelling growth story backed by disciplined capital allocation and expanding operating leverage. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$68.00 Mean target$71.00 High · most bullish analyst$76.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $68.00 Regulatory delays push the approval of the licensed ultra-rare disease candidate into late 2026 or 2027, and the KHINDIVI label expansion faces FDA pushback. Commercial execution on HEMANGEOL and DESMODA progresses slower than anticipated due to payer reimbursement hurdles, keeping 2026 revenues flat relative to the current run rate and compressing EBITDA margins below 25%. Base CaseCentral scenario $71.00 Matches the consensus meanEton successfully delivers on its raised 2026 guidance, with revenues exceeding $120 million and Adjusted EBITDA margins of at least 30%. The commercial portfolio continues its steady growth trajectory, supported by the launch of the newly licensed ultra-rare disease generic in mid-2026 and the filing of the KHINDIVI label expansion in Q3 2026. Operating cash flows remain strong, funding bolt-on acquisitions without dilutive equity raises. Bull CaseUpside scenario $76.00 Rapid commercial adoption of newly launched DESMODA and relaunched HEMANGEOL, combined with faster-than-expected patient acquisition for GALZIN and INCRELEX, drives 2026 revenues well past $130 million. The company achieves an Adjusted EBITDA margin of 35% in 2026 and reaches its 50% margin target ahead of schedule in 2027. Pipeline candidates like ET-700 deliver outstanding clinical results, unlocking significant peak sales potential. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |